Trade Ideas Flow

$IAM's hidden metabolic bet: what the filings show, what they don't, and what it's worth Disclosure: I am long $IAM at an average of $9.95. Research, not advice. The short version • Iambic told investors it works on metabolic disease, and its CEO repeated it on the record. That line was added to the IPO filing late, between the July and August drafts. • The clue is GPCRs, the receptor family that GLP-1 and every other big obesity target belongs to. Iambic has a head of GPCR biology, and its audit chair sits on the board of a company with a $2.2B Novo Nordisk obesity deal. • Peptides are a model capability, not a program. The prospectus never uses the word. • The obesity pill race has moved on. The liver problem that killed Pfizer's pills has been solved by at least four groups. The open lanes are oral amylin, next-gen receptor targets and longer-lasting peptides. • One typical early obesity deal pays about $80M to $110M upfront. That is a quarter to a third of Iambic's enterprise value. Nothing is priced in today. 1. Iambic said "metabolic". Then it said it again. The confidential IPO draft of 24 July 2026 does not mention metabolic disease. The next draft, on 28 August, adds this sentence, which survives unchanged into the final prospectus: "we are engaged in a number of discovery stage programs in indications, including oncology, metabolic disease and endocrinology, which we estimate represent an over $70 billion in aggregate global commercial opportunity." The same draft adds that Iambic has eight discovery programs, wholly owned and partnered, and expects up to 25 in 2027. It also says partnerships are expanding the platform to new target classes, "for example, G protein-coupled receptors". On 16 October the CEO, Tom Miller, was asked about moving beyond cancer. About the wholly owned pipeline, he said: "It includes metabolic disease. It includes endocrinology." (BioPharma Dive) The company's own documents do not all agree: • The Enchant v3 page (21 September) lists the pipeline areas as oncology, neuroscience and inflammation and immunology. Metabolic is not listed. • The risk factor on moving beyond cancer names neurology, gastrointestinal and inflammation only. • There is no use-of-proceeds line for metabolic work and no metabolic row on the pipeline page. My read: something metabolic existed or was planned by late August, and Iambic chose to name it before the IPO. It has not said what. 2. Why GPCRs are the tell A GPCR (G protein-coupled receptor) is a switch on the surface of a cell. The big obesity targets are GPCRs: the GLP-1, GIP, glucagon, amylin and MC4R receptors. Lilly's new obesity pill, Foundayo, is a small molecule that flips the GLP-1 switch. What Iambic has: • A GPCR team. An "Executive Director, Head of GPCR Biology" has appeared on Iambic's LinkedIn page since at least February 2025. • GPCR agonist work. From March 2025 to March 2026 the pipeline page showed a partnered "GPCR target / allosteric agonist / neurological" program. That is very likely Lundbeck (my inference). It is the only disclosed work in which Iambic designs a pill that switches a GPCR on, which is the same job an oral GLP-1 does. It is in brain disease, not obesity. • A boardroom view of the playbook. Audit chair Shalini Sharp has been a director of Septerna since January 2024. In May 2025 Septerna signed an obesity deal with Novo Nordisk worth up to about $2.2B, with more than $200M upfront and near-term. It covers oral small molecules on GPCR targets "including GLP-1, GIP, and glucagon receptors". None of this proves a program. It shows the skills, the people and the template are in the building. 3. Peptides: the capability is real, the program isn't • Enchant v3 (September 2026) lists peptides as a new capability, citing "the success of GLP-1s". It publishes no peptide results. • In NeuralPLexer3's paper, protein–peptide docking was its strongest category: 85.1% against 76.6% for AlphaFold-Multimer. That is 47 cases with overlapping uncertainty ranges, and AlphaFold 3 was not compared. • The prospectus never uses the word "peptide". I found no peptide patent, no peptide program and no peptide job post in the live board or 65 archived ones. So "dark horse in peptides" is a stretch today. "Dark horse in oral metabolic pills" fits the evidence better. 4. Where the obesity market actually is The market is enormous: • Lilly's tirzepatide (Mounjaro and Zepbound) sold about $36.5B in 2025 and $43.8B in the first nine months of 2026. • Novo's semaglutide franchise sold about DKK 228B (roughly $35B) in 2025. Pills are coming, but the peptide pill is winning so far. In the first nine months of 2026 the Wegovy pill (oral semaglutide, a peptide) sold DKK 10.9B, roughly $1.7B. Foundayo (a small molecule) sold $281M. Part of that is timing: the Wegovy pill launched in January, Foundayo in April. Oral peptides are wasteful. The FDA label puts oral semaglutide's absorption at about 0.4% to 1%. The Wegovy pill is 25 mg a day against 2.4 mg a week injected. The liver problem is mostly solved. Pfizer stopped lotiglipron in 2023 and danuglipron in April 2025 over liver safety. Since then, orforglipron (Foundayo), Structure's aleniglipron, AstraZeneca's elecoglipron and MindRank's MDR-001 have reported no liver signal. MDR-001 was designed with AI property prediction and has been in Phase 3 in China since January 2026. "AI fixes the GLP-1 pill" is already a crowded story. What is still open: • Weight loss. Pills take off about 11% to 15%, while injections reach 20% to 29% (retatrutide 28.7%). • Oral amylin. Amylin is the hottest next-generation target. The only oral small-molecule amylin drug in human trials is Structure's ACCG-2671, in Phase 1 since December 2025. • Longer-lasting peptides. Monthly shots and better half-lives. Half-life prediction is exactly what Enchant's first benchmark measured. That is where an AI chemistry platform with a GPCR group could matter. 5. What it could be worth What pharma paid upfront for early-stage (discovery or preclinical) obesity assets, 2023 to 2026: • Novo – Lexicon (2025), preclinical, oral: $45M • Lilly – Nimbus (Jan 2026), discovery, oral: $55M incl. near-term • Merck – Hansoh (Dec 2024), preclinical, oral: $112M • Novo – Valo (Jan 2025), discovery, AI: $190M incl. equity and near-term • Novo – Septerna (May 2025), discovery, oral: >$200M incl. near-term • Novo – Hengrui (Sep 2026), Phase 1-ready, oral: $300M The median across seven early deals is about $112M. Counting only clean upfronts (four deals), it is about $79M. For IAM: one such deal is $1.65 to $2.35 a share, about 25% to 36% of today's roughly $313M enterprise value. The market pays nothing for it today. The reality check: Structure Therapeutics. Structure has a Phase 3-ready oral GLP-1 and the only oral amylin pill in the clinic. Its enterprise value on 11 November was about $276M ($1.51B market value less $1.24B of cash), below Iambic's. The market is not handing out multiples for oral obesity pipelines. For Iambic, the value of a metabolic program arrives as partner cash, not as a re-rating. 6. What to watch • Patents. International applications publish about 18 months after filing, so anything filed after about May 2025 is still invisible. A GPCR or incretin family appearing in 2027 would be the first hard proof. • SEC comment letters. Once released, they may show whether the SEC asked about the August metabolic addition. • The first 10-Q (around 30 November) and the J.P. Morgan conference (January): any named metabolic target. • The job board. In vivo obesity pharmacology or GPCR metabolic roles. • Bayer. The June 2026 deal's therapeutic area is still undisclosed. Bayer's focus is cardio-renal, oncology and women's health. Bottom line There is no named metabolic program, no peptide program and no metabolic partner. There is a late-added prospectus line, a CEO who said it twice in one breath, a GPCR team, a director who has seen a $2.2B Novo GPCR deal from the inside, and a deal market that pays about $80M to $110M upfront for exactly this stage. At about $313M of enterprise value, that is a free option on top of the HER2 drug, not the thesis. Size it that way. Long $IAM at $9.95. Not advice.